Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1605) 1605
Publication (138) 138
Book Review (39) 39
Book Chapter (9) 9
Conference Proceeding (4) 4
Book / eBook (2) 2
Magazine Article (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1470) 1470
progressive multifocal leukoencephalopathy (768) 768
male (653) 653
index medicus (622) 622
female (559) 559
leukoencephalopathy, progressive multifocal - etiology (548) 548
adult (502) 502
middle aged (429) 429
clinical neurology (410) 410
magnetic resonance imaging (373) 373
neurosciences (289) 289
brain - pathology (273) 273
leukoencephalopathy, progressive multifocal - diagnosis (273) 273
leukoencephalopathy, progressive multifocal - pathology (248) 248
leukoencephalopathy (215) 215
aged (207) 207
jc virus (207) 207
multiple sclerosis (183) 183
neurology (181) 181
natalizumab (170) 170
leukoencephalopathy, progressive multifocal - complications (155) 155
central-nervous-system (150) 150
animals (148) 148
immunology (146) 146
acquired immunodeficiency syndrome - complications (141) 141
aids (141) 141
risk factors (132) 132
diagnosis (128) 128
hiv infections - complications (128) 128
disease (125) 125
infection (125) 125
diagnosis, differential (122) 122
health aspects (114) 114
infectious diseases (113) 113
leukoencephalopathy, progressive multifocal - virology (113) 113
medicine & public health (113) 113
tomography, x-ray computed (113) 113
hiv (110) 110
child (108) 108
cerebrospinal-fluid (107) 107
jc virus - isolation & purification (106) 106
leukoencephalopathy, progressive multifocal - drug therapy (105) 105
medicine, general & internal (105) 105
leukoencephalopathy, progressive multifocal (103) 103
oncology (100) 100
virology (100) 100
brain (98) 98
care and treatment (94) 94
immunosuppressive agents - adverse effects (93) 93
adolescent (91) 91
fatal outcome (91) 91
pathology (88) 88
viruses (85) 85
antibodies, monoclonal - adverse effects (84) 84
multiple sclerosis - drug therapy (84) 84
therapy (83) 83
treatment outcome (80) 80
jc virus - genetics (78) 78
leukoencephalopathy, progressive multifocal - immunology (78) 78
article (77) 77
biopsy (77) 77
antibodies, monoclonal - therapeutic use (76) 76
rituximab (76) 76
retrospective studies (75) 75
drug therapy (74) 74
multiple-sclerosis (74) 74
central nervous system (73) 73
encephalitis (72) 72
active antiretroviral therapy (71) 71
hematology (71) 71
immunosuppressive agents - therapeutic use (71) 71
patients (71) 71
pharmacology & pharmacy (71) 71
patient (70) 70
pml (69) 69
transplantation (69) 69
immunocompromised host (68) 68
infections (67) 67
child, preschool (66) 66
research (66) 66
virus diseases (66) 66
surgery (65) 65
disease progression (64) 64
placebo-controlled trial (64) 64
human-immunodeficiency-virus (63) 63
polymerase chain reaction (63) 63
hiv infections - drug therapy (61) 61
immunosuppression (60) 60
leukoencephalopathy, progressive multifocal - chemically induced (60) 60
leukoencephalopathy, progressive multifocal - diagnostic imaging (60) 60
abridged index medicus (59) 59
nervous system diseases - etiology (59) 59
prognosis (59) 59
immunotherapy (56) 56
brain - diagnostic imaging (55) 55
encephalopathy (55) 55
cancer (54) 54
psychiatry (54) 54
development and progression (52) 52
double-blind (51) 51
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1434) 1434
French (53) 53
Spanish (41) 41
Japanese (38) 38
German (25) 25
Polish (8) 8
Italian (5) 5
Russian (5) 5
Czech (4) 4
Hungarian (3) 3
Danish (2) 2
Dutch (2) 2
Chinese (1) 1
Hebrew (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
by Cortese, Irene and Muranski, Pawel and Enose-Akahata, Yoshimi and Ha, Seung-Kwon and Smith, Bryan and Monaco, MariaChiara and Ryschkewitsch, Caroline and Major, Eugene O and Ohayon, Joan and Schindler, Matthew K and Beck, Erin and Reoma, Lauren B and Jacobson, Steve and Reich, Daniel S and Nath, Avindra
The New England Journal of Medicine, ISSN 0028-4793, 04/2019, Volume 380, Issue 17, pp. 1597 - 1605
Eight patients with progressive multifocal leukoencephalopathy associated with chronic lymphocytic leukemia, HIV infection, lymphoma, or idiopathic lymphopenia... 
CIDOFOVIR | MEDICINE, GENERAL & INTERNAL | Immune Reconstitution Inflammatory Syndrome - etiology | Brain - diagnostic imaging | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | CD4-Positive T-Lymphocytes - physiology | Viral Load | Adult | Female | Leukoencephalopathy, Progressive Multifocal - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Down-Regulation | Leukoencephalopathy, Progressive Multifocal - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Cerebrospinal Fluid - virology | CD8-Positive T-Lymphocytes - physiology | White Matter - pathology | Magnetic Resonance Imaging | White Matter - diagnostic imaging | JC Virus - isolation & purification | Lymphocyte Count | Aged | Leukoencephalopathy, Progressive Multifocal - diagnostic imaging | Immunologic Factors - therapeutic use | Drug therapy | Leukoencephalopathy | Nuclear magnetic resonance--NMR | PD-1 protein | Laboratories | CD8 antigen | Body weight | Immune clearance | Infections | Cerebrospinal fluid | Progressive multifocal leukoencephalopathy | Disability | Pembrolizumab | Lymphocytes | Peripheral blood | Drug dosages | Movement disorders | Antigens | Immune response | Cytokines | Patients | CD4 antigen | Immune checkpoint | Cell death | Lymphomas | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
by Milojkovic, Dragana and Wathes, Rowan and Moule, Simon
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 197 - 198
Ruxolitinib blocks Janus kinase (JAK) 1 and 2 signaling, a pathway involved in host defenses. A case is reported in which progressive multifocal... 
MEDICINE, GENERAL & INTERNAL | NATALIZUMAB | Janus Kinases - antagonists & inhibitors | Primary Myelofibrosis - drug therapy | Primary Myelofibrosis - complications | Humans | Brain - pathology | Leukoencephalopathy, Progressive Multifocal - etiology | Male | Aged | Pyrazoles - adverse effects | Nuclear magnetic resonance--NMR | Myelofibrosis | Biopsy | Ataxia | Janus kinase | Leukoencephalopathy | Progressive multifocal leukoencephalopathy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
by Lindå, Hans and von Heijne, Anders and Major, Eugene O and Ryschkewitsch, Caroline and Berg, Johan and Olsson, Tomas and Martin, Claes
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 11, pp. 1081 - 1087
This report describes progressive multifocal leukoencephalopathy in a patient who was receiving natalizumab therapy for multiple sclerosis. Plasma exchange was... 
MEDICINE, GENERAL & INTERNAL | RELAPSING MULTIPLE-SCLEROSIS | CONTROLLED TRIAL | THERAPY | CROHNS-DISEASE | JC VIRUS-DNA | CEREBROSPINAL-FLUID | PCR | Leukoencephalopathy, Progressive Multifocal - immunology | Immune Reconstitution Inflammatory Syndrome - etiology | JC Virus - immunology | Natalizumab | JC Virus - genetics | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Integrin alpha4 - immunology | DNA, Viral - blood | Multiple Sclerosis - complications | Antibodies, Monoclonal, Humanized | Leukoencephalopathy, Progressive Multifocal - chemically induced | Magnetic Resonance Imaging | Polymerase Chain Reaction | Brain - pathology | Multiple Sclerosis - pathology | Adult | Multiple Sclerosis - drug therapy | Case studies | Multiple sclerosis | Care and treatment | Diagnosis | Leukoencephalopathy, Progressive multifocal | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Progressive multifocal leukoencephalopathy in transplant recipients
by Mateen, Farrah J and Muralidharan, RajaNandini and Carone, Marco and van de Beek, Diederik and Harrison, Daniel M and Aksamit, Allen J and Gould, Mary S and Clifford, David B and Nath, Avina
Annals of neurology, ISSN 0364-5134, 2011, Volume 70, Issue 2, pp. 305 - 322
Transplant recipients are at risk of developing progressive multifocal leukoencephalopathy (PML), a rare demyelinating disorder caused by oligodendrocyte... 
INFECTIONS | POLYOMAVIRUS | BONE-MARROW-TRANSPLANTATION | LONG-TERM SURVIVAL | LYMPHOMA | RENAL-TRANSPLANTATION | PATIENT | COMPLICATIONS | NATALIZUMAB | STEM-CELL TRANSPLANTATION | NEUROSCIENCES | CLINICAL NEUROLOGY | Humans | Middle Aged | Risk Factors | Transplants - adverse effects | Leukoencephalopathy, Progressive Multifocal - virology | Male | Survival Rate | Leukoencephalopathy, Progressive Multifocal - diagnosis | PubMed | Young Adult | JC Virus | Adolescent | Leukoencephalopathy, Progressive Multifocal - etiology | Adult | Female | Aged | Retrospective Studies | Cohort Studies | Confidence intervals | Bone marrow | Transplants & implants | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Progressive multifocal leukoencephalopathy after treatment with nivolumab
by Martinot, Martin and Ahle, Guido and Petrosyan, Inesa and Martinez, Camille and Gorun, Dragos M and Mohseni-Zadeh, Mahsa and Fafi-Kremer, Samira and Tebacher-Alt, Martine
Emerging Infectious Diseases, ISSN 1080-6040, 08/2018, Volume 24, Issue 8, pp. 1594 - 1596
Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive... 
IMMUNE | INFECTIOUS DISEASES | INFECTIOUS-DISEASES | THERAPY | EVENTS | IMMUNOLOGY | CANCER | Hodgkin Disease - diagnostic imaging | Hodgkin Disease - virology | Antineoplastic Agents, Immunological - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Hydrocortisone - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hodgkin Disease - drug therapy | Female | Leukoencephalopathy, Progressive Multifocal - virology | Nivolumab - adverse effects | Magnetic Resonance Imaging | Antineoplastic Agents, Immunological - adverse effects | Viremia - pathology | Viremia - virology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | JC Virus - isolation & purification | Leukoencephalopathy, Progressive Multifocal - etiology | Viremia - diagnostic imaging | Aged | Leukoencephalopathy, Progressive Multifocal - diagnostic imaging | Leukoencephalopathy, Progressive Multifocal - pathology | Programmed Cell Death 1 Receptor - immunology | Viremia - etiology | Programmed Cell Death 1 Receptor - genetics | Nivolumab - administration & dosage | Care and treatment | Immunotherapy | Leukoencephalopathy, Progressive multifocal | Monoclonal antibodies | Lymphomas | T cells | Health aspects | Apoptosis | immune checkpoint inhibitor | viruses | nivolumab | HIV | progressive multifocal leukoencephalopathy | JC virus | encephalitis | AIDS and other retroviruses | meningtitis | Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab | Research Letter | meningtitis/encephalaitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
by Clifford, David B, MD and DeLuca, Andrea, MD and Simpson, David M, MD and Arendt, Gabriele, MD and Giovannoni, Gavin, MBBCh and Nath, Avindra, MD
Lancet Neurology, The, ISSN 1474-4422, 2010, Volume 9, Issue 4, pp. 438 - 446
Summary Background Treatment of multiple sclerosis with natalizumab is complicated by rare occurrence of progressive multifocal leukoencephalopathy (PML).... 
Neurology | ASYMPTOMATIC REACTIVATION | SURVIVAL | PLASMA | EFFICACY | JC VIRUS | DISEASE | THERAPIES | INFECTION | CEREBROSPINAL-FLUID | PML | CLINICAL NEUROLOGY | Antibodies, Monoclonal, Humanized | Leukoencephalopathy, Progressive Multifocal - therapy | Natalizumab | Humans | Antibodies, Monoclonal - adverse effects | Leukoencephalopathy, Progressive Multifocal - etiology | Antibodies, Monoclonal - therapeutic use | Immunologic Factors - adverse effects | Leukoencephalopathy, Progressive Multifocal - diagnosis | Leukoencephalopathy, Progressive Multifocal - epidemiology | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Medical colleges | Multiple sclerosis | Care and treatment | Leukoencephalopathy, Progressive multifocal | Cerebrospinal fluid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
by Vermersch, P and Kappos, L and Gold, R and Foley, J.F and Olsson, T and Cadavid, D and Bozic, C and Richman, S
Neurology, ISSN 0028-3878, 05/2011, Volume 76, Issue 20, pp. 1697 - 1704
Objective: Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic... 
PATIENT | QUALITY-OF-LIFE | MULTIPLE-SCLEROSIS | CANCER | CLINICAL NEUROLOGY | Predictive Value of Tests | Prognosis | Natalizumab | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Cause of Death | Socioeconomic Factors | Antibodies, Monoclonal, Humanized | Karnofsky Performance Status | Anti-Inflammatory Agents - therapeutic use | Product Surveillance, Postmarketing | Adult | Female | Mitoxantrone - therapeutic use | Disability Evaluation | Treatment Outcome | Leukoencephalopathy, Progressive Multifocal - mortality | Multiple Sclerosis - complications | Magnetic Resonance Imaging | Survival Analysis | Leukoencephalopathy, Progressive Multifocal - etiology | Early Diagnosis | Multiple Sclerosis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Progressive multifocal leukoencephalopathy and newer biological agents
by Berger, Joseph R
Drug Safety, ISSN 0114-5916, 2010, Volume 33, Issue 11, pp. 969 - 983
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the brain due to a polyoma virus, JC virus. Despite the ubiquity of this... 
Polyomavirus-infections | Natalizumab, adverse reactions | Monoclonal-antibodies, adverse reactions | Efalizumab, adverse reactions | Progressive-multifocal- leukoencephalopathy, pathogenesis | Progressive-multifocal-leukoencephalopathy, drug-induced | Demyelinating-disorders, drug-induced | Mycophenolate-mofetil, adverse reactions | Rituximab, adverse reactions | SYSTEMIC-LUPUS-ERYTHEMATOSUS | MULTIPLE-SCLEROSIS PATIENTS | JC VIRUS-DNA | BONE-MARROW | IMMUNE-DEFICIENCY SYNDROME | HIV-NEGATIVE PATIENTS | B-CELLS | PERIPHERAL-BLOOD LEUKOCYTES | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HUMAN POLYOMAVIRUS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MYCOPHENOLATE-MOFETIL | JC Virus - immunology | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Leukoencephalopathy, Progressive Multifocal - drug therapy | Leukoencephalopathy, Progressive Multifocal - virology | Antibodies, Monoclonal - therapeutic use | Risk Management | Mycophenolic Acid - adverse effects | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | JC Virus - pathogenicity | Leukoencephalopathy, Progressive Multifocal - etiology | Immunosuppressive Agents - adverse effects | Leukoencephalopathy, Progressive Multifocal - pathology
Journal Article
Details down arrow
9. Full Text Progressive multifocal leukoencephalopathy in autoimmune diseases
by Palazzo, Elisabeth and Yahia, Salim Ahmed
Joint Bone Spine, ISSN 1297-319X, 2011, Volume 79, Issue 4, pp. 351 - 355
Abstract Progressive multifocal leukoencephalopathy (PML) is a subacute central nervous system infection due to reactivation of the JC virus. Most reported... 
Internal Medicine | Rheumatology | Systemic lupus erythematosus | Rheumatoid arthritis | Rituximab | Autoimmune disease | Leflunomide | Methotrexate | Progressive multifocal leukoencephalopathy | B-LYMPHOCYTES | SYSTEMIC-LUPUS-ERYTHEMATOSUS | VIRUS | NATALIZUMAB | RHEUMATOLOGY | ARTHRITIS | DOSE ORAL METHOTREXATE | THERAPY | PATIENT | RHEUMATIC-DISEASES | Comorbidity | Lupus Erythematosus, Systemic - epidemiology | Humans | Antibodies, Monoclonal - adverse effects | Arthritis, Rheumatoid - epidemiology | JC Virus - physiology | Virus Activation - drug effects | Infliximab | Arthritis, Rheumatoid - drug therapy | Autoimmune Diseases | Lupus Erythematosus, Systemic - drug therapy | Antirheumatic Agents - adverse effects | JC Virus - pathogenicity | Leukoencephalopathy, Progressive Multifocal - etiology | Drug Therapy, Combination | Antibodies, Monoclonal, Murine-Derived - adverse effects | Glucocorticoids - adverse effects | Isoxazoles - adverse effects | Leukoencephalopathy, Progressive Multifocal - epidemiology | Lupus | Corticosteroids | HIV patients | Diagnostic imaging | Leukoencephalopathy | Immunosuppressive agents | Rheumatoid factor | Immunotherapy | Leukoencephalopathy, Progressive multifocal | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
by Scarpazza, Cristina and Signori, Alessio and Prosperini, Luca and Sormani, Maria Pia and Cosottini, Mirco and Capra, Ruggero and Gerevini, Simonetta and Italian PML Grp and Italian PML Group
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 03/2019, Volume 90, Issue 3, pp. 261 - 267
ObjectiveEarly diagnosis of natalizumab-related progressive multifocal leucoencephalopathy (NTZ-PML) in multiple sclerosis has been deemed a major priority by... 
STATEMENT | SURVIVAL | SURGERY | ASYMPTOMATIC PML | PLASMA | MULTIPLE-SCLEROSIS | MRI | PSYCHIATRY | GUIDELINES | NATALIZUMAB-ASSOCIATED PML | RISK | CLINICAL NEUROLOGY | Humans | Middle Aged | Male | Multiple Sclerosis - diagnostic imaging | Young Adult | Magnetic Resonance Imaging | Natalizumab - therapeutic use | Leukoencephalopathy, Progressive Multifocal - etiology | Multiple Sclerosis - pathology | Adult | Female | Italy | Leukoencephalopathy, Progressive Multifocal - diagnostic imaging | Leukoencephalopathy, Progressive Multifocal - pathology | Retrospective Studies | Early Diagnosis | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Neurology | Multiple sclerosis | Nuclear magnetic resonance--NMR | Brain research | Surveillance | Laboratories | Medical diagnosis | Patients | Psychiatry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
by Ho, Pei-Ran and Koendgen, Harold and Campbell, Nolan and Haddock, Bill and Richman, Sandra and Chang, Ih
The Lancet Neurology, ISSN 1474-4422, 11/2017, Volume 16, Issue 11, pp. 925 - 933
Previous estimates of risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis receiving natalizumab were stratified by... 
SUPPORT | PLASMA | DXSELECT(TM) | LONG-TERM SAFETY | SERUM | TREATED PATIENTS | STRATIFICATION | PML | CLINICAL NEUROLOGY | JC VIRUS-ANTIBODIES | JC Virus - immunology | Multiple Sclerosis - blood | Humans | Middle Aged | Natalizumab - adverse effects | Risk Factors | Kaplan-Meier Estimate | Male | Clinical Studies as Topic | Leukoencephalopathy, Progressive Multifocal - chemically induced | PubMed - statistics & numerical data | Leukoencephalopathy, Progressive Multifocal - etiology | Multiple Sclerosis - immunology | Adult | Antibodies - blood | Female | Immunologic Factors - adverse effects | Cohort Studies | Multiple Sclerosis - drug therapy | Medical research | Care and treatment | Multiple sclerosis | Leukoencephalopathy, Progressive multifocal | Clinical trials | Medicine, Experimental | Risk factors | Immunoglobulins | Statistical analysis | Data processing | Patients | Estimates | Leukoencephalopathy | Progressive multifocal leukoencephalopathy | Studies | Neurology | Algorithms | Risk assessment | Population | Clinical medicine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
by Major, Eugene O and Yousry, Tarek A and Clifford, David B
The Lancet Neurology, ISSN 1474-4422, 05/2018, Volume 17, Issue 5, pp. 467 - 480
Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating disease of the CNS caused by the JC virus (JCV) that occurs in patients... 
CUNNINGHAM VIRUS-ANTIBODY | PLASMA-EXCHANGE | HUMAN BRAIN | RECONSTITUTION INFLAMMATORY SYNDROME | BONE-MARROW | NATALIZUMAB-ASSOCIATED PML | JC-VIRUS | DIMETHYL FUMARATE | BK VIRUS | CEREBROSPINAL-FLUID | CLINICAL NEUROLOGY | Leukoencephalopathy, Progressive Multifocal - immunology | Leukoencephalopathy, Progressive Multifocal - chemically induced | Humans | Natalizumab - adverse effects | Leukoencephalopathy, Progressive Multifocal - etiology | Leukoencephalopathy, Progressive Multifocal - virology | Immunologic Factors - adverse effects | Multiple Sclerosis - drug therapy | Medical colleges | Medical research | Neurosciences | Multiple sclerosis | Medicine, Experimental | Disease susceptibility | Drug therapy | Molecular biology | Health aspects | Leukoencephalopathy | Brain | Disease | Immunomodulation | Pathogenesis | Central nervous system | Infections | Patients | Progressive multifocal leukoencephalopathy | Magnetic resonance imaging | Surveillance | Demyelination | Binding sites | Deoxyribonucleic acid--DNA | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights